Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Sanofis venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

• In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaning… [+13923 chars]

पूरा लेख पढ़ें →